Top Ways to Trade a Potential Treatment for Obesity

Jun 09, 2022
single science glass flask with double exposure scientist or researcher holding tube in chemistry blue laboratory with stock market information background

The obesity epidemic is still bursting at the seams.

According to the World Health Organization (WHO) obesity has tripled in size over the last 50 years. In 2016, they note, 1.9 billion adults were overweight around the world. Of those, 650 million were considered obese. Just in the U.S., nearly 34% of adults and up to 20% of children are obese. By 2030, almost half of U.S. adults will be considered obese. By 2030, almost half of U.S. adults will be considered obese. Along with such weight-issues, there can be complications with heart disease, stroke, type 2 diabetes, and several types of cancer.

However, we may be nearing a potential solution.

In fact, Novo Nordisk (NVO) and Eli Lilly (LLY) are seeing big weight loss numbers in clinical trials of a new class of drugs called incretins.

“Both companies met stock analysts during the ADA meeting, and the talks focused on the exciting prospects for a new class of drugs called incretins. In a Tuesday meeting, Lilly reviewed a Phase 3 study published over the weekend in the New England Journal of Medicine, in which patients on the highest dose of Lilly’s diabetes drug tirzepatide lost an average of 52 pounds over 18 months,” as noted by Barron’s.

Also, as noted by Barron’s, “If the FDA approves the Lilly drug for obesity marketing, tirzepatide could launch in mid-2023. J.P. Morgan analyst Chris Schott rates Lilly at Outperform, and believes the drug will eventually surpass $10 billion in obesity sales, on top of over $12 billion in sales for diabetes.”

In short, this could be a game-changer, and could send stocks, like LLY to the moon.